Anthony Cavazos, MD
Geriatric Medicine · New Providence, NJNPI 1104944263
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.0% of the total across 221 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 23 manufacturers reported payments, led by Merz North America, Inc. at 38.1% of the total. Reporting peaked in 2019 at $1,317 and has fallen 78.2% since, to $287 in 2025. Among geriatric medicine clinicians in NJ with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 221 payments — averaging $23.02 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Merz North America, Inc.$2K
- Novo Nordisk$788
- Lilly USA, LLC$593
- Antares Pharma, Inc.$513
- AbbVie$368
- AstraZeneca$215
- plus $673 from 17 others
What the payments were for
- Speaking & faculty fees$391%
- Food & beverage$5,03799%
- Education$120%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Merz North America, Inc. | 20 | $1,939 |
| Novo Nordisk | 57 | $788 |
| Lilly USA, LLC | 40 | $593 |
| Antares Pharma, Inc. | 28 | $513 |
| AbbVie(2 entities) | 18 | $368 |
| AstraZeneca | 15 | $215 |
| Amgen | 7 | $105 |
| Amarin Pharma, Inc. | 7 | $95 |
| Halozyme Inc | 4 | $88 |
| Tolmar, Inc. | 4 | $58 |
| Azurity Pharmaceuticals, Inc. | 3 | $51 |
| Acerus Pharmaceuticals Corporation | 3 | $45 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 3 | $43 |
| Acella Pharmaceuticals, LLC | 2 | $37 |
| Verity Pharmaceuticals Inc. | 2 | $35 |
| Currax Pharmaceuticals LLC | 1 | $17 |
| Johnson & Johnson | 1 | $16 |
| Echosens North America, Inc. | 1 | $15 |
| Jazz Pharmaceuticals Inc. | 1 | $14 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $14 |
| Eisai Inc. | 1 | $14 |
| Sanofi-aventis U.S. LLC | 1 | $13 |
| Teva Pharmaceuticals USA, Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- XEOMIN$874
How this compares
$5,088 in reported general payments places this provider in the 90th percentile of 165 geriatric medicine providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| GenotropinSomatropin | 16 | $111,656 |
| MounjaroTirzepatide | 26 | $26,834 |
| TrulicityDulaglutide | 22 | $21,472 |
| OzempicSemaglutide | 18 | $19,680 |
| LinzessLinaclotide | 11 | $5,262 |
| Butalbital-Acetaminophen-CaffeButalb/Acetaminophen/Caffeine | 13 | $1,306 |
| Duloxetine Hcl | 15 | $656 |
| Liothyronine Sodium | 12 | $400 |
| Atorvastatin Calcium | 21 | $302 |
| Levothyroxine Sodium | 18 | $254 |
| Alprazolam | 41 | $233 |
| Tramadol Hcl | 17 | $123 |
| Rosuvastatin Calcium | 12 | $115 |
| Metformin Hcl | 20 | $94 |
| Fluconazole | 14 | $94 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $593 | $48,30648 claims |
| Novo NordiskOzempic | $788 | $19,68018 claims |
| AbbVieLinzess | $368 | $5,26211 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 165 geriatric medicine providers in New Jersey.
Other geriatric medicine in New Providence
- Albert RiddleHaworth$524K
- Gamil MakarClifton$82K
- Joshua Shua HaimManchester$45K
- Pradip ShahWest Caldwell$27K
- Gregorio GuillenPerth Amboy$8K
- Ketankumar VaidyaEdison$8K
- Cheng-An MaoClifton$8K
- Theresa RedlingLivingston$7K
- Sarita RastogiHackensack$7K
- Leslie FeiginDenville$7K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.